Clomiphene citrate treatment for late onset hypogonadism: rise and fall

Detalhes bibliográficos
Autor(a) principal: Marconi,Marcelo
Data de Publicação: 2016
Outros Autores: Souper,Renato, Hartmann,Jonathan, Alvarez,Matías, Fuentes,Ignacio, Guarda,Francisco J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000601190
Resumo: ABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.
id SBU-1_e19d67cd5fd1750cf9c4316b5a1092c4
oai_identifier_str oai:scielo:S1677-55382016000601190
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Clomiphene citrate treatment for late onset hypogonadism: rise and fallHypogonadismClomipheneTestosteroneTherapeuticsABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.Sociedade Brasileira de Urologia2016-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000601190International braz j urol v.42 n.6 2016reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2016.0112info:eu-repo/semantics/openAccessMarconi,MarceloSouper,RenatoHartmann,JonathanAlvarez,MatíasFuentes,IgnacioGuarda,Francisco J.eng2016-11-22T00:00:00Zoai:scielo:S1677-55382016000601190Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2016-11-22T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Clomiphene citrate treatment for late onset hypogonadism: rise and fall
title Clomiphene citrate treatment for late onset hypogonadism: rise and fall
spellingShingle Clomiphene citrate treatment for late onset hypogonadism: rise and fall
Marconi,Marcelo
Hypogonadism
Clomiphene
Testosterone
Therapeutics
title_short Clomiphene citrate treatment for late onset hypogonadism: rise and fall
title_full Clomiphene citrate treatment for late onset hypogonadism: rise and fall
title_fullStr Clomiphene citrate treatment for late onset hypogonadism: rise and fall
title_full_unstemmed Clomiphene citrate treatment for late onset hypogonadism: rise and fall
title_sort Clomiphene citrate treatment for late onset hypogonadism: rise and fall
author Marconi,Marcelo
author_facet Marconi,Marcelo
Souper,Renato
Hartmann,Jonathan
Alvarez,Matías
Fuentes,Ignacio
Guarda,Francisco J.
author_role author
author2 Souper,Renato
Hartmann,Jonathan
Alvarez,Matías
Fuentes,Ignacio
Guarda,Francisco J.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Marconi,Marcelo
Souper,Renato
Hartmann,Jonathan
Alvarez,Matías
Fuentes,Ignacio
Guarda,Francisco J.
dc.subject.por.fl_str_mv Hypogonadism
Clomiphene
Testosterone
Therapeutics
topic Hypogonadism
Clomiphene
Testosterone
Therapeutics
description ABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.
publishDate 2016
dc.date.none.fl_str_mv 2016-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000601190
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000601190
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2016.0112
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.42 n.6 2016
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318075350089728